Licensing

Upsher-Smith, the Maple Grove, Minn.-based subsidiary of Japan’s Sawai Pharmaceuticals, has re-introduced its Klor-Con (potassium chloride for oral solution). The company received approval from the Food and Drug Administration for the product that joins its generics portfolio. The company noted that the relaunched product would be available with a new NDC number.

The product has a U.S. market size of $98 million for the 12 months ended September 2017, according to data from IQVIA.

LIVONIA, Mich. — Online healthcare and IT certification training school MedCerts is partnering with the Michigan Pharmacists Association for an effort that it says will bring higher-level training to pharmacy technicians. The partnership will offer state associations across the United States discounted access to online training for members to achieve certification goals, MedCerts said.

TORONTO, Ontario — A new poll commissioned by the Ontario Pharmacists Association has found that patients in the province would trust their pharmacist to dispense medical marijuana. The poll, which comes as the OPA pushes for regulatory changes that would allow pharmacists to dispense medical cannabis, found that 70% of patients think pharmacists should be involved in doing so.

WASHINGTON — The President’s Commission on Combating Drug Addiction and the Opioid Crisis has issued its final report with 56 recommendations on how to address prescription drug abuse and misuse. The report, issued at the commission’s final meeting Wednesday, includes such recommendations as providing federal funding and programs to target opioid abuse and misuses, addiction prevention efforts and prescription drug management program enhancements, among others.

SILVER SPRING, Md. — The Food and Drug Administration has approved the first generic from Taiwan-based drug development company Sunny Pharmtech and generic development company Vitruvias Therapeutics. The companies announced the approval of its generic lidocaine ointment, 5%.

MUMBAI — Lupin is looking to a longtime pharmaceutical industry veteran to head its business development and global mergers and acquisitions functions. The company named Jim Loerop its chief corporate development officer Monday, charging him with integrating its business development, licensing and M&A teams to drive its business strategy.

ALEXANDRIA, Va. — EAS Consulting Group on Thursday welcomed Timothy Stewart as the new independent advisor for dietary supplements.  

Stewart has been an independent consultant for EAS since 2013 and has proven to be an invaluable asset to dietary supplement clients, taking on the most challenging projects and providing sound solutions that offer a way forward in the complex world of dietary supplement FDA regulations.

DUBLIN — Allergan and its subsidiaries on Monday announced that it has reached a settlement regarding its litigation with Famy Care Limited relating to Allergan's Restasis (cyclosporine ophthalmic emulsion) 0.05%.

The patents relative to Restasis are listed in the Orange Book and expire on Aug. 27, 2024, Allergan stated.